Figure - uploaded by Damodar Gaddam
Content may be subject to copyright.
Source publication
Nutritional status has an important effect on quality of life and sense of wellbeing in patients
with any type of cancer. Recent data have more definitively indicated that nutritional counselling
could lead to increased quality of life of patients with different types of cancers. The main
intention of our review is to initiate dietary counselling i...
Citations
... As the cancer treatment may deteriorate the weight of the patients, there is a chance of increasing in the number of underweight patients thereby reducing their QOL. Since most of patients were low socioeconomic, there is a need to implement the dietary counselling in this study site according to their financial background [26] . Laboratory investigations like Hb, ESR were analyzed. ...
... As the cancer treatment may deteriorate the weight of the patients, there is a chance of increasing in the number of underweight patients thereby reducing their QOL. Since most of patients were low socioeconomic, there is a need to implement the dietary counselling in this study site according to their financial background[26]. ...
... As the cancer treatment may deteriorate the weight of the patients, there is a chance of increasing in the number of underweight patients thereby reducing their QOL. Since most of patients were low socioeconomic, there is a need to implement the dietary counselling in this study site according to their financial background [26] . Laboratory investigations like Hb, ESR were analyzed. ...
Over the last decade, quality of life investigations of cancer patients' have became a critical evaluation parameter in the clinical cancer research and treatment evaluation programs. This study was carried out in a 1200 bed tertiary care teaching hospital, MGM Hospital, located at Warangal, India. Present study assessed the overall quality of life, symptoms of patients affected by breast, head and neck, cervical and stomach cancers by using guidelines and modules of The European Organisation for Research and Treatment of Cancer. The assessment was carried out in two phases, as review I at ≤2 cycles and review II at ≥5 cycles of treatment. Data were analyzed for 104 individuals with the mean age of 46.1±11.2 years. The evaluation was characterised as functional scale and symptom scale. In the functional scale physical, and role functions were significant (P<0.05) in all the 4 types of cancers studied. Additional, future perspective, social and emotional functions were observed to be significant in breast cancer, head and neck cancer and cervical cancer, respectively. Where as in symptom scale pain was observed to be significant for all cancers studied. Individually, breast cancer patient also showed significant parameters like fatigue, arm symptoms, and upset by hair loss. Head and neck cancer patients had insomnia and diarrhoea as additional significant symptom scale parameters. In cervical cancer patients, fatigue, insomnia, menopausal symptoms, and in stomach cancer patients, nausea and vomiting, dysphagia, reflex symptoms and eating restrictions were significantly affected. Most of the findings are similar to past studies in the respective type of cancer patients which shows that, quality of life was mostly influenced by the above mentioned factors and have some interesting implications for management and treatment of cancer.
... [16] Since, the prevalence of underweight was more among these patients, there is a great need to provide dietary counseling based on their financial and educational status. [18] Elevation of liver enzymes and function tests can often be difficult to determine in a patient clinical setting. Our investigation revealed that the incidence of hepatotoxicity associated with Inj. ...
Hepatic dysfunction in the cancer unit has a significant impact on patient outcomes. The therapeutic application of anthracycline antibiotics are limited by side-effects mainly myelosuppression, chronic cardiotoxicity, and hepatotoxicity.
To assess the risk of Hepatotoxicity in breast cancer patients receiving Inj. Doxorubicin.
The investigation was a prospective study that was conducted in cancer patients receiving Inj. Doxorubicin doses of 50 mg/m(2), and 75 mg/m(2) at a South Indian tertiary care hospital. Sample collection was carried out from pre-chemotherapy to 4(th) cycle. Serum glutamic oxaloacetic transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), direct bilirubin and total bilirubin were assessed to determine hepatotoxicity. Data were analyzed using unpaired t-test, Pearson correlation using Graph-Pad Prism version 5.00 for Windows, Graph-Pad Software, San Diego, California, USA, www.graphpad.com.
Breast cancer patients comprised 37% (49/132) of the total female cancer patient population, of which 46 patients with a mean age of 46.6 (13.4) years were included and 30.4% (14/46) patients were developed hepatotoxicity. The mean standard deviation of SGOT, SGPT, direct bilirubin, total bilirubin in the pre-chemotherapy cycle to fourth chemotherapy cycle were found to be 21.97 (5.798) U/L and 181.3 (103.6) U/L, 23.17 (6.237) U/L and 147.6 (90.9) U/L, 0.1351 (0.1186) mg/dL and 0.5445 (0.4587) mg/dL, 0.3094 (1.346) mg/dL and 2.7163 (1.898) mg/dL simultaneously where P < 0.05 which were statistically significant.
There exist a strong correlation between the use of Inj. Doxorubicin and risk for developing hepatotoxicity. The health-care professionals dealing with breast cancer patients need to have awareness for hepatotoxicity with the use of Inj. Doxorubicin therapy.
... ment and found that 36.9% (17/46) were underweight, 56.5% (26/46) were having normal weight and 6.5% (3/46) were having overweight. There were no obese patients in this study group. Since, the prevalence of underweight was more among these patients, there is a great need to provide dietary counseling based on their financial and educational status. [18] Elevation of liver enzymes and function tests can often be difficult to determine in a patient clinical setting. Our investigation revealed that the incidence of hepatotoxicity associated with Inj. Doxorubicin was 30.4% (14/46) based upon our predefined criteria which were supported by the study of Llesuy and Arnaiz. [19] In a study by ...
